 Sulfasalazine
"Sulfasalazine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
| Descriptor ID |
D012460
|
| MeSH Number(s) |
D02.065.884.730 D02.886.590.700.730
|
| Concept/Terms |
Sulfasalazine- Sulfasalazine
- Salicylazosulfapyridine
- Sulphasalazine
- Salazosulfapyridine
Colo-Pleon- Colo-Pleon
- Colo Pleon
- Pleon
- Sanofi Synthelabo Brand of Sulfasalazine
- Henning Berlin Brand of Sulfasalazine
Ulcol- Ulcol
- Alphapharm Brand of Sulfasalazine
Ucine- Ucine
- Ashbourne Brand of Sulfasalazine
Azulfidine- Azulfidine
- Azulfadine
- Salazopyrin
- Pfizer Brand of Sulfasalazine
- Sulfasalazine Pfizer Brand
- Pyralin EN
- Asulfidine
- Azulfidine EN
- EN, Azulfidine
|
Below are MeSH descriptors whose meaning is more general than "Sulfasalazine".
Below are MeSH descriptors whose meaning is more specific than "Sulfasalazine".
This graph shows the total number of publications written about "Sulfasalazine" by people in this website by year, and whether "Sulfasalazine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1984 | 0 | 1 | 1 | | 1985 | 0 | 1 | 1 | | 1988 | 0 | 1 | 1 | | 1989 | 0 | 1 | 1 | | 1990 | 2 | 1 | 3 | | 1991 | 2 | 1 | 3 | | 1993 | 1 | 0 | 1 | | 1994 | 0 | 1 | 1 | | 1995 | 2 | 0 | 2 | | 1996 | 0 | 1 | 1 | | 1998 | 0 | 2 | 2 | | 2000 | 0 | 2 | 2 | | 2002 | 0 | 1 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 0 | 2 | 2 | | 2005 | 1 | 1 | 2 | | 2006 | 1 | 2 | 3 | | 2007 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2012 | 1 | 0 | 1 | | 2016 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Sulfasalazine" by people in Profiles.
-
Lim WC, Wang Y, MacDonald JK, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2016 Jul 03; 7:CD008870.
-
Tabit CE, Holbrook M, Shenouda SM, Dohadwala MM, Widlansky ME, Frame AA, Kim BH, Duess MA, Kluge MA, Levit A, Keaney JF, Vita JA, Hamburg NM. Effect of sulfasalazine on inflammation and endothelial function in patients with established coronary artery disease. Vasc Med. 2012 Apr; 17(2):101-7.
-
Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2010 Dec 08; (12):CD008870.
-
Terdiman JP, Steinbuch M, Blumentals WA, Ullman TA, Rubin DT. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007 Apr; 13(4):367-71.
-
Rubin DT, LoSavio A, Yadron N, Huo D, Hanauer SB. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006 Nov; 4(11):1346-50.
-
Hanauer SB. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther. 2006 Oct; 24 Suppl 3:37-40.
-
Zeöld A, Doleschall M, Haffner MC, Capelo LP, Menyhért J, Liposits Z, da Silva WS, Bianco AC, Kacskovics I, Fekete C, Gereben B. Characterization of the nuclear factor-kappa B responsiveness of the human dio2 gene. Endocrinology. 2006 Sep; 147(9):4419-29.
-
Hanauer SB. The case for using 5-aminosalicyclates in Crohn's disease: pro. Inflamm Bowel Dis. 2005 Jun; 11(6):609-12.
-
Kles KA, Vavricka SR, Turner JR, Musch MW, Hanauer SB, Chang EB. Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum. Inflamm Bowel Dis. 2005 Mar; 11(3):253-7.
-
Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol. 2005 Feb; 166(2):409-19.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|